Paper9756776
Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.
Takei M and 4 others. Antimicrob Agents Chemother, 1998. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Papers, record 9756776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9756776
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Bacteria | Major topic |
| Enzyme Inhibitors | Major topic |
| Fluoroquinolones | Major topic |
| Topoisomerase II Inhibitors | Major topic |
| Gatifloxacin | |
| HeLa Cells | |
| Humans |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1963290 | Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/1963290 | PubMed |
| 2 | 2556080 | Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2556080 | PubMed |
| 3 | 1332587 | In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1332587 | PubMed |
| 4 | 8517696 | Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8517696 | PubMed |
| 5 | 8227000 | Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. | J Biol Chem | 1993 | https://conductscience.org/library/papers/8227000 | PubMed |
| 6 | 7904438 | Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/7904438 | PubMed |
| 7 | 8203860 | In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8203860 | PubMed |
| 8 | 8092836 | Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8092836 | PubMed |
| 9 | 7997176 | Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. | Mol Microbiol | 1994 | https://conductscience.org/library/papers/7997176 | PubMed |
| 10 | 7826854 | Roles of DNA topoisomerases in chromosomal replication and segregation. | Adv Pharmacol | 1994 | https://conductscience.org/library/papers/7826854 | PubMed |
| 11 | 7872758 | Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7872758 | PubMed |
| 12 | 7783632 | The twisted 'life' of DNA in the cell: bacterial topoisomerases. | Mol Microbiol | 1995 | https://conductscience.org/library/papers/7783632 | PubMed |
| 13 | 8524852 | Topoisomerase IV is a target of quinolones in Escherichia coli. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/8524852 | PubMed |
| 14 | 7492103 | Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. | Antimicrob Agents Chemother | 1995 | https://conductscience.org/library/papers/7492103 | PubMed |
| 15 | 8723458 | Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8723458 | PubMed |
| 16 | 8843298 | Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8843298 | PubMed |
| 17 | 8851598 | Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/8851598 | PubMed |
| 18 | 9124828 | Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. | Antimicrob Agents Chemother | 1996 | https://conductscience.org/library/papers/9124828 | PubMed |
| 19 | 9278055 | Crystal structure of the breakage-reunion domain of DNA gyrase. | Nature | 1997 | https://conductscience.org/library/papers/9278055 | PubMed |
| 20 | 9293187 | DNA gyrase, topoisomerase IV, and the 4-quinolones. | Microbiol Mol Biol Rev | 1997 | https://conductscience.org/library/papers/9293187 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40435237 | Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586. | Sci Adv | 2025 | https://conductscience.org/library/papers/40435237 | PubMed |
| 36417527 | Top2a promotes the development of social behavior via PRC2 and H3K27me3. | Sci Adv | 2022 | https://conductscience.org/library/papers/36417527 | PubMed |
| 35096778 | Design of a Controlled-Release Delivery Composite of Antibacterial Agent Gatifloxacin by Spherical Silica Nanocarrier. | Front Chem | 2021 | https://conductscience.org/library/papers/35096778 | PubMed |
| 29311442 | Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions. | Exp Anim | 2018 | https://conductscience.org/library/papers/29311442 | PubMed |
| 23357772 | Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23357772 | PubMed |
| 12234876 | Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12234876 | PubMed |
| 12121916 | Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12121916 | PubMed |
| 11790160 | Gatifloxacin: a review of its use in the management of bacterial infections. | Drugs | 2002 | https://conductscience.org/library/papers/11790160 | PubMed |
| 11709337 | Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11709337 | PubMed |
| 11257024 | Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11257024 | PubMed |
| 10582891 | Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10582891 | PubMed |
| 10551438 | Gatifloxacin. | Drugs | 1999 | https://conductscience.org/library/papers/10551438 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TOP2A | 7153 | PubTator's text mining | https://conductscience.org/library/genes/7153 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9756776
GET https://conductscience.org/api/papers/v1/9756776/references?page=2